Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Esser S, Brunetta J, Inciarte A, Levy I, D'Arminio Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito M, Liu CE, Altuntas Aydın O, Thorpe D, Heinzkill M, Marongiu A, Cassidy T, Haubrich R, D'Amato L, Robineau O. Esser S, et al. Among authors: inciarte a. HIV Med. 2024 Apr;25(4):440-453. doi: 10.1111/hiv.13593. Epub 2023 Dec 26. HIV Med. 2024. PMID: 38148567
Post-exposure prophylaxis for HIV infection in sexual assault victims.
Inciarte A, Leal L, Masfarre L, Gonzalez E, Diaz-Brito V, Lucero C, Garcia-Pindado J, León A, García F; Sexual Assault Victims Study Group. Inciarte A, et al. HIV Med. 2020 Jan;21(1):43-52. doi: 10.1111/hiv.12797. Epub 2019 Oct 11. HIV Med. 2020. PMID: 31603619 Free PMC article.
Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
Fernández I, de Lazzari E, Inciarte A, Diaz-Brito V, Milinkovic A, Arenas-Pinto A, Etcheverrry F, García F, Leal L; HIV-PEP Group. Fernández I, et al. Among authors: inciarte a. HIV Med. 2021 Mar;22(3):218-224. doi: 10.1111/hiv.12964. Epub 2020 Oct 27. HIV Med. 2021. PMID: 33108035 Free article.
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project.
Bruguera A, Egea-Cortés L, Mesías-Gazmuri J, Palacio-Vieira J, Forero CG, Miranda C, Saumoy M, Fernández E, Navarro G, Orti A, Miró JM, Casabona J, Reyes-Urueña J; PISCS Study Group. Bruguera A, et al. HIV Med. 2024 Apr;25(4):424-439. doi: 10.1111/hiv.13590. Epub 2023 Dec 13. HIV Med. 2024. PMID: 38092529
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Chivite I, et al. Among authors: inciarte a. J Antimicrob Chemother. 2024 May 17:dkae138. doi: 10.1093/jac/dkae138. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38758191
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
Martínez-Serra A, De Lazzari E, Berrocal L, Foncillas A, De La Mora L, Inciarte A, Chivite I, González-Cordón A, Martínez-Rebollar M, Torres B, Laguno M, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Martínez-Serra A, et al. Among authors: inciarte a. J Antimicrob Chemother. 2023 Aug 2;78(8):1955-1962. doi: 10.1093/jac/dkad189. J Antimicrob Chemother. 2023. PMID: 37311224
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A, Borjabad B, Berrocal L, Blanch J, Inciarte A, Chivite I, Gonzalez-Cordon A, Torres B, Ambrosioni J, Martinez-Rebollar M, Laguno M, De La Mora L, Foncillas A, Sempere A, Rodriguez A, Solbes E, Llobet R, Miro JM, Mallolas J, Blanco JL, De Lazzari E, Martinez E. Rocabert A, et al. Among authors: inciarte a. J Antimicrob Chemother. 2023 Dec 1;78(12):2961-2967. doi: 10.1093/jac/dkad338. J Antimicrob Chemother. 2023. PMID: 37875023
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years' Experience.
Ugarte A, de la Mora L, García D, Martínez-Rebollar M, de Lazzari E, Torres B, Inciarte A, Ambrosioni J, Chivite I, Solbes E, de Loredo N, Del Carlo GF, González-Cordón A, Blanco JL, Martínez E, Mallolas J, Laguno M. Ugarte A, et al. Among authors: inciarte a. Infect Dis Ther. 2023 Feb;12(2):425-442. doi: 10.1007/s40121-022-00733-6. Epub 2022 Dec 15. Infect Dis Ther. 2023. PMID: 36520330 Free PMC article.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).
Inciarte A, Ugarte A, Martínez-Rebollar M, Torres B, Fernández E, Berrocal L, Laguno M, De la Mora L, De Lazzari E, Callau P, Chivite I, González-Cordón A, Solbes E, Rico V, Barrero L, Blanco JL, Martínez E, Ambrosioni J, Mallolas J; DORAVIPEP Study Group. Inciarte A, et al. Open Forum Infect Dis. 2023 Jul 19;10(8):ofad374. doi: 10.1093/ofid/ofad374. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539061 Free PMC article.
70 results